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The rpoB gene codes for the RNA polymerase b subunit, which is the target of rifampicin, an essential
drug in the treatment of tuberculosis and other mycobacterial infections. This gene is present in all
bacteria, but its length and nucleotide sequence vary between bacterial species, including mycobacteria.
Mutations in the rpoB gene alter the structure of this protein and cause drug resistance. To describe the
resistance-associated mutations, the scientiﬁc and medical communities have been using, since 1993, a
numbering system based on the Escherichia coli sequence annotation. Using E. coli reference for
describing mutations in mycobacteria leads to misunderstandings, particularly with the increasing use of
whole genome sequencing, which brought an alternative numbering system based on theMycobacterium
tuberculosis rpoB sequence. We propose using a consensus numbering system for the reporting of
resistance mutations based on the reference genomes from the species interrogated (such as strain
H37Rv for M. tuberculosis). This manuscript provides the necessary ﬁgures and tables allowing re-
searchers, microbiologists and clinicians to easily convert other annotation systems into one common
language. E. Andre, CMI 2016;▪:1
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rifampicin, also named rifampin in the USA, is the key drug of the
ﬁrst-line treatment regimen for tuberculosis (TB), a disease affecting
9.6 million persons per year [1]. Multidrug-resistant TB (MDR-TB),
deﬁned as disease caused by Mycobacterium tuberculosis complex
strains resistant to rifampicin and isoniazid, requires prolonged andemmanuel.andre@outlook.be
r Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).
t al., Consensus numbering sy
ogy and Infection (2016), httmore complex administration of alternative treatment regimens
including second-line anti-TB drugs, and is associated with poorer
treatment outcome [2,3]. Isoniazid-resistance is caused by different
mutations affecting different genes [4], but the molecular basis of
RIF resistance is simpler, as virtually all resistant strains present a
mutation in the rpoB gene, and 95% of these are located within a
small 81-bp region named the rifampicin-resistance determining
region (RRDR) [5]. Consequently, molecular assays were easily
developed to detect rifampicin resistance, and several commercial
kits are now available and used worldwide [6e8]. Furthermore,
molecular detection of rifampicin resistance is used as a surrogateof Clinical Microbiology and Infectious Diseases. This is an open access article under
stem for the rifampicin resistance-associated rpoB gene mutations in
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resistant cases are not resistant to isoniazid [9e11]. The different
species of the M. tuberculosis complex present similar resistance
mutations [12e16].
Mutations in the rpoB gene are also associated with rifampicin
resistance among other mycobacterial species, such as in Mycobac-
terium leprae causing leprosy [17,18] and Mycobacterium kansasii
causingmainly respiratory infections in immunocompetent patients
with also disseminated infections in immunocompromised patients
[19]. Rifampicin resistance in M. leprae was described as associated
with dapsone resistance in patients with MDR-leprosy. For these
leprosy cases, the standard treatment regimen needs to be switched
to a 2-year treatment combining daily second-line agents such as
ﬂuoroquinolones [20]. In M. kansasii, rifampicin is also a key
component of treatment. Here rpoB gene mutations also lead to
rifampicin resistance [19] and the need for alternative regimens [21].
Rifampicin resistance is caused by a structural alteration in the
RNA polymerase b subunit, an enzyme coded by the rpoB gene. This
mechanism was ﬁrst described in 1981 for Escherichia coli [22,23],
and it is therefore not speciﬁc tomycobacteria, although the clinical
utility of rpoB mutations characterization is more important for TB
and leprosy than for any other bacterial infections [24].
It was only in 1993 that Telenti et al. ﬁrst suggested that
rifampicin resistance in M. tuberculosis complex was associated
with mutations in the rpoB gene, and observed a high similarity of
the amino acids coded between several bacterial species including
E. coli, M. tuberculosis complex and M. leprae [5]. Since the muta-
tions described in that work were identiﬁed in an rpoB region that
aligned with the RRDR of E. coli, Telenti et al. proposed an anno-
tation system based on the E. coli genetic sequence. The authors
probably underestimated how the diversity of the rpoB nucleotide
sequence would later affect our ability to correctly report single
nucleotide mutations causing amino acid substitutions [25e27].
Furthermore, although the authors recognized that resistance
mutations may be located outside the RRDR, they did not pay
attention to the low similarity between E. coli and M. tuberculosis
complex in rpoB outside the RRDR. The existence and epidemio-
logical importance of these ‘non-RRDR’ resistance mutations was
later conﬁrmed [28e30]. Nevertheless, this annotation systemwas
rapidly adopted [31] and is still often used today forM. tuberculosis
complex [32,33], M. leprae [34,35] and M. kansasii [19,36]. It was
only recently that authors started using a species-speciﬁc
numbering system [29,37e39]. This has caused some confusion
because the same mutations are now named differently depending
on the author, the year and the journal that published the work. For
M. leprae, rpoB mutations were numbered ﬁrst according to the
gene sequence ofM. leprae rpoB gene cloned in a cosmid, where the
codon 425 corresponds to the codon 531 in E. coli and this was used
to establish the WHO resistance surveillance network [40e42].
More recently, this expert group decided to switch to the
numbering system of the M. leprae genome taking as a reference
the genome sequence of the Tamil Nadu (TN) strain [37,43,44].
In this manuscript, we discuss the limitations of the traditional
numbering system and propose to shift towards a more natural
numbering system based on the mycobacterial reference se-
quences. This should allow better communication between labo-
ratories, especially at a time when whole genome sequencing is
becoming the standard for detecting drug resistance [39], improved
disease surveillance [45,46] and faster spreading of scientiﬁc
knowledge in the medical community.
Diversity of rpoB numbering systems
Among M. tuberculosis complex, M. leprae and M. kansasii, the
nucleotide similarity lies between 86% and 88% for the entire rpoBPlease cite this article in press as: Andre E, et al., Consensus numbering sy
pathogenic mycobacteria, Clinical Microbiology and Infection (2016), httgene and is slightly higher in the 81-bp RRDR (between 88.9% and
92.6%). The similarity of these mycobacteria with E. coli is less (47%
and 74% for the rpoB gene and the RRDR respectively) [47].
Furthermore, the rpoB genes of E. coli, M. tuberculosis complex,
M. leprae andM. kansasii differ in length (4029, 3519, 3537 and 3540
base pairs, respectively). These differences explain the variable shift
between the E. coli-based annotation and the mycobacterial
sequence-based numbering systems. At present, resistance muta-
tions outside the RRDR have only been characterized for
M. tuberculosis complex. This situation leads to an even more
complex situation, as the shift from the E. coli numbering system to
the M. tuberculosis complex numbering system is different
depending on the location of the resistance mutation (i.e. þ24 for
the M. tuberculosis complex codon 170, and 81 for the other co-
dons of interest).
Table 1 and Fig. 1 represent the codons that are most frequently
associated with resistance mutations across the three mycobacte-
rial species.Mycobacterium tuberculosis complex and E. coli present
identical amino-acids only for eight of the nine codons, and not
nine as initially suggested by Telenti et al. [5]. Only three of the nine
codons show the same sequence.
Reporting systems derived from the use of commercial assays
The commercial assays have developed several mutation
detection systems as an alternative to gene sequencing. These as-
says report rifampicin resistance based on the detection of muta-
tions in the wild-type (WT) sequence of the RRDR by molecular
beacons [48,49] or hybridization [8,37,50]. These tests include
probes that bind to WT sequences (Xpert MTB/RIF (M. tuberculosis/
rifampicin), Cepheid), eventually combined with additional probes
binding to mutated sites (line probe assays InnoLipa RifTB, Inno-
genetics, Ghent, Belgium; GenoType MTBDRplus and GenoType
lepraeDR, Hain Lifescience, Nehren, Germany), so silent mutations
or mutations not associated with resistance can occasionally
generate false-positive results [50e54].
The reporting format of these commercial assays can be
‘matched’ with the speciﬁc sequence covered by each probe (Xpert
MTB/RIF), or the combination of WT and mutation bands
(MTBDRplus, LepraeDR) as illustrated in Fig. 2.
In practice, the majority of rpoB mutations are located at
M. tuberculosis complex codons 435, 445 and 450 (also named 516,
526 and 531, respectively, using the E. coli numbering system) and at
codons 456 and 441 in M. leprae. As an example, in the presence of
the mutation Ser450Leu, the Xpert MTB/RIF assay will report a
negative ‘Probe E’, signing the presence of a mutation located be-
tween positions 447 and 452. For the same mutation, the
MTBDRplus V2.0 assay will report a negative ‘WT8’ band associated
with a positive ‘MUT3’ band. Although complex laboratory networks
generally use a combination of these tests, the concordance between
the results of each test is rarely veriﬁed in routine conditions
because of the difﬁculties in comparing between the numbering
systems. The number of commercial assays available for TB di-
agnostics and detection of rifampicin resistance will increase in the
future [55], and each of these tests will probably come with its own
reporting format. If this is the case, the efforts required for under-
standing and solving discordant results will increase further [32].
Consequences of different coexisting numbering systems
The sequencing methods used to identify mutations are
currently shifting from traditional Sanger sequencing to whole
genome sequencing [56,57]. Although bothmethods are used today
and will continue to coexist for some years, high-throughput
sequencing technologies present multiple advantages includingstem for the rifampicin resistance-associated rpoB gene mutations in
p://dx.doi.org/10.1016/j.cmi.2016.09.006
Fig. 1. (a) Alignment of the nucleotide sequences for the rpoB genes of Escherichia coli, Mycobacterium tuberculosis H37Rv (MTB), Mycobacteirum leprae TN (ML) and Mycobacterium
kansasii ATCC 12478 (MK). Rifampicin-resistance-determining region (RRDR) is highlighted in yellow. Red boxes show rifampicin resistance mediating mutation outside the RRDR.
(b) Alignment of 81-bp RRDR of E. coli, M. tuberculosis complex, M. leprae and M. kansasii. Bars above the nucleotide sequences indicate the position of the seven codons frequently
associated with rifampicin resistance, using the annotation system speciﬁc to each species. Nucleotide and amino acid differences are highlighted. Graph created using GENEIOUS,
Biomatters, version 9.1).
Table 1
Conversion table between the two co-existing numbering systems for the most frequent rpoB mutations associated with rifampicin resistance among Mycobacterium
tuberculosis complex, Mycobacterium leprae and Mycobacterium kansasii
M. tuberculosis H37Rv 
(GenBank AL123456)
M. leprae TN
(GenBank AL583923)
M. kansasii ATCC 12478
(GenBank CP006835)
Escherichia coli 
(GenBank V00339)
WT nucleoƟde 
sequence 
(amino acid)
Codon posiƟon
(conversion from 
E. coli 
numbering) 
WT nucleoƟde 
sequence 
(amino acid)
Codon posiƟon 
(conversion from 
E. coli 
numbering) 
WT nucleoƟde 
sequence 
(amino acid)
Codon posiƟon 
(conversion from 
E. coli 
numbering) 
WT nucleoƟde 
sequence 
(amino acid)
Codon posiƟon
GTC (Val) 170 (+24) GTT (Val) 146 
GGC (Gly) 426 (–81) GGC (Gly) 432 (–75) GTT (Gly) 507
CTG (Leu) 430 (–81) CTG (Leu) 436 (–75) CTG (Leu) 511
CAA (Gln) 432 (–81) CAG (Gln) 438 (–75) CAG (Gln) 442 (–71) CAG (Gln) 513
GAC (Asp) 435 (–81) GAT (Asp) 441 (–75) GAC (Asp) 445 (–71) GTC (Val) 516
CAC (His) 445 (–81) CAC (His) 451 (–75) CAC (His) 455 (–71) CAC (His) 526
TCG (Ser) 450 (–81) TGC (Ser) 456 (–75) TCG (Ser) 460 (–71) TCC (Ser) 531
CTG (Leu) 452 (–81) CTG (Leu) 458 (–75) CTC (Leu) 533
ATC (Ile) 491 (–81) ATC (Ile) 572
WT, wild-type. The homology in regard to the nucleotide and the amino acid sequences of the different mycobacteria and E. coli is highlighted in green. Differences are
highlighted in red.
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Fig. 2. (a) Alignment ofMycobacterium tuberculosis complex rifampicin-resistance-determining region (RRDR) sequence with the targets of Xpert MTB/RIF and the MTBDRplus V2.0
commercial assays. The red bars represent the location of the most common codons associated with rifampicin resistance conferring mutations. The orange bars indicate the regions
covered by the ﬁve probes of the Xpert MTB/RIF assay. The green bars represent the regions covered by the eight wild-type (WT) and four mutation bands of the GENOTYPE MTBDRPLUS
V2.0 assay. (b) Alignment ofMycobacterium leprae RRDR sequence with the targets of the LepraeDR commercial assay. The blue bars represent the location of the codons associated
with rifampicin resistance conferring mutations, the four WT bands and the two mutation bands. Graph created using GENEIOUS, Biomatters, version 9.1.
E. Andre et al. / Clinical Microbiology and Infection xxx (2016) 1e64the ability to sequence simultaneously several genes associated
with antimicrobial resistance. The inherent principles of
sequencing require the use of an annotation system based on a
consensus sequence, and starting at the beginning of each gene.
Therefore, using E. coli as a reference sequence for M. tuberculosis
complex andM. leprae is not reasonable, and hampers the necessity
to correctly and precisely annotate genetic sequences and identify
drug resistance-conferring mutations.
One example of how the use of different annotation systems can
lead to major misunderstandings is the recent report from
Swaziland. The authors reported that approximately one-third of
the rifampicin-resistant M. tuberculosis complex strains were
associated with the Ile491Phe mutation, a mutation that was sup-
posedly never reported before, at least based on theM. tuberculosis
complex numbering system [29]. However, this mutation is
equivalent to Ile572Phe in the E. coli numbering system, a mutation
that was described in rifampicin-resistant M. tuberculosis complex
strains from many countries [58e63]. Sanchez-Padilla et al. used
the M. tuberculosis complex-based annotation system, despite the
fact that this denomination is almost non-existent in the scientiﬁc
literature.
Perspectives
The characterization of the rpoB gene inM. tuberculosis complex
strains, including the precise localization of mutations conferring
rifampicin resistance, is probably one of the most common mo-
lecular biology analyses performed for clinical purposesworldwide.
Unfortunately, a standardized reporting format cannot be obtained
because of the coexistence of different numbering systems used by
commercial and non-commercial assays targeting this gene.
There are three main reasons why the E. coli and the device-
speciﬁc numbering systems should be changed to one standard-
ized system based on the sequence of the reference strain of each
species, namely H37Rv (GenBank reference AL123456) forPlease cite this article in press as: Andre E, et al., Consensus numbering sy
pathogenic mycobacteria, Clinical Microbiology and Infection (2016), httM. tuberculosis complex,M. leprae Tamil Nadu (GenBank reference
AL583923) for M. leprae and M. kansasii ATCC 12478 (GenBank
reference CP006835) forM. kansasii. First, although the homology
between E. coli and M. tuberculosis complex is relatively high in
the RRDR, it is signiﬁcantly lower for the rest of the rpoB gene.
Therefore, although the correspondence between the E. coli and
M. tuberculosis complex numbering systems is relatively easy
within the hotspot region (the difference is 81 codons), such a
‘simple conversion’ does not work when looking at a resistance
mutation located outside this speciﬁc region (the difference be-
tween theM. tuberculosis complex codon 170 and its equivalent in
the E. coli genome is 24) [28,64]. Second, the sequencing method
used to identify mutations is currently shifting from traditional
Sanger sequencing methods to whole genome sequencing. As the
genome of M. tuberculosis complex reference strain H37Rv is
standard strain used worldwide [65], any variant numbering
nomenclature should be based on this sequence [29,39,56]. Such
revision has been previously proposed for the gyrB gene associ-
ated with ﬂuoroquinolone resistance, for which four different
reporting systems have been used, resulting in mutation location
discrepancies [66]. Finally, many of the rpoBmutations reported in
clinical strains so far have distinctive characteristics in conferring
phenotypic resistance, including varying cross-resistance to rifa-
butin. Therefore, a precise nomenclature for the location of the
mutations is essential from a laboratory diagnostic perspective,
especially for the development of individualized treatment regi-
mens [25,32].
Accordingly, the use of divergent numbering systems for rpoB
mutations generates risks related to miscommunication and delays
the transfer of scientiﬁc knowledge into clinical care.
The aim of this manuscript is to facilitate the shift towards
this universal annotation system, including the necessary ﬁgures
and tables allowing researchers, microbiologists and clinicians to
easily ‘translate’ other annotation systems into one common
language.stem for the rifampicin resistance-associated rpoB gene mutations in
p://dx.doi.org/10.1016/j.cmi.2016.09.006
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